Jorge Gallardo-Cartagena, MD, MPH
Postdoctoral FellowAbout
Research
Publications
2026
Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey
Gallardo-Cartagena J, German-Quiñones D, Konda K, Buchbinder S, Sanchez J, Altice F. Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey. JMIR Public Health And Surveillance 2026, 12: e84982. PMID: 42447457, PMCID: PMC13367761, DOI: 10.2196/84982.Peer-Reviewed Original ResearchIdentifying Implementation Gaps in the HIV Prevention Cascade among Peruvian Men Who Have Sex with Men
Gallardo-Cartagena J, Oliveros D, Cabello R, Benites C, Buchbinder S, Konda K, Altice F, Sanchez J. Identifying Implementation Gaps in the HIV Prevention Cascade among Peruvian Men Who Have Sex with Men. AIDS And Behavior 2026, 1-17. PMID: 42084836, DOI: 10.1007/s10461-026-05147-w.Peer-Reviewed Original ResearchViral variant but not host factors associate with SARS-CoV-2 viral kinetics
Hahn W, Fisher L, Ward A, Grant S, Yen C, Randhawa A, Li X, Ramirez S, Espy N, Hural J, Hanke J, Roychoudhury P, Kelley C, Rouphael N, Cantos V, Pinto J, Cahn P, Manentsa M, Makhema J, Samaneka W, Bhondai-Mhuri M, Stranix-Chibanda L, Losso M, Garcia E, Innes C, Chinula L, Lama J, Gallardo-Cartagena J, Kabengele C, Chilengi R, Nchabeleng M, Tieu H, Hoagland B, Grinsztejn B, Brumskine W, Ahmed K, Wallis C, Greninger A, Corey L, Hyrien O. Viral variant but not host factors associate with SARS-CoV-2 viral kinetics. Communications Medicine 2026, 6: 346. PMID: 41998406, PMCID: PMC13272808, DOI: 10.1038/s43856-026-01588-5.Peer-Reviewed Original ResearchChallenges and Opportunities for Improved Tuberculosis and HIV Prevention in South America
Quispe-Juli C, Gallardo-Cartagena J, Otero L, Andrade B, Croda J, Cantos V, Mendoza-Ticona A, Valderrama-Beltrán S, Sequera G, Huaman M. Challenges and Opportunities for Improved Tuberculosis and HIV Prevention in South America. Open Forum Infectious Diseases 2026, 13: ofag157. PMID: 41918956, PMCID: PMC13034732, DOI: 10.1093/ofid/ofag157.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCoordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans
Schuster D, Li S, Mielke D, Seaton K, Brackett C, Li K, Shen X, Wesley M, Eisel N, Yates N, Zhang L, Sawant S, De Rosa S, Cohen K, Stanfield-Oakley S, Sholukh A, St. Germain R, Li X, Hu J, Premkumar L, Gallardo-Cartagena J, Randhawa A, Dennison S, Hural J, Corey L, Karuna S, McElrath M, Ferrari G, Hyrien O, Tomaras G. Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans. IScience 2026, 29: 115277. PMID: 42016169, PMCID: PMC13092704, DOI: 10.1016/j.isci.2026.115277.Peer-Reviewed Original ResearchImplementation of Daily Oral PrEP at HIV/AIDS Service Organizations in Lima, Peru: Early Findings From the PrEP PERU Demonstration Study
Ramírez P, Lankowski A, Gallardo-Cartagena J, Gonzales P, Valencia J, Lama J, León M, Salvatierra J, Sanchez H, Cabello R, Konda K, Sanchez J, Group O. Implementation of Daily Oral PrEP at HIV/AIDS Service Organizations in Lima, Peru: Early Findings From the PrEP PERU Demonstration Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2026, 25: 23259582251411793. PMID: 41493894, PMCID: PMC12775336, DOI: 10.1177/23259582251411793.Peer-Reviewed Original Research
2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
Buchbinder S, Guzman S, Sanchez J, Willems W, Stieh D, van Duijn J, van Rosmalen M, Hendriks J, Nijs S, Lavreys L, Paez C, Grinzstejn B, Hutter J, Mann P, Madero J, Cahn P, Castagna A, Truyers C, Roels S, Gilbert P, Carone M, Luedtke A, Corey L, Pau M, Tomaka F, Team H, Abdalian S, Pinto J, Andrasik M, Andriesen J, da Cunha C, Barbera M, Broder G, Buchbinder S, May C, Cahn P, Casapia M, Cassetti L, Castagna A, Corbelli G, Crofoot G, da Silva Pilotto J, De Jesus E, De La Grecca R, Del Rio C, Doblecki-Lewis S, Dougherty K, Eaton N, Edupuganti S, Estrada V, Rodriguez I, Flores J, Frank I, Franklin M, Franks J, Cartagena J, Ganoza C, Del Toro M, Goepfert P, Gonzalez R, Hernandez L, Gorgolas M, Goulart S, Greninger A, Grinsztejn B, Grove D, Hanke J, Vidal J, Hural J, Jones M, Kalams S, Kallas E, Kamel L, Katafias A, Kublin J, Lacerda M, Lama J, Losso M, Lupo S, Madruga J, Martin T, Mayer K, Mazzotta V, McClennen R, McElrath J, Moltó-Marhuenda J, Morales-Ramirez J, Mussini C, Souza T, Novak R, Rinn L, Román A, Thomas D, Segura P, Madero J, Sobieszczyk M, Sopher C, Stirewalt M, Swaminathan S, Szetela B, Van Tieu H, Tindale I, Valencia J, Wallace S, Walsh S, Wilvich H. Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet HIV 2025, 12: e823-e835. PMID: 41314741, PMCID: PMC13455713, DOI: 10.1016/s2352-3018(25)00195-x.Peer-Reviewed Original ResearchHigh Willingness to Use and Recommend Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention in Peru
Gallardo-Cartagena J, German-Quiñones D, Rosas-Benancio F, Tafur K, Velásquez-Velásquez D, Cabello R, Konda K, Celum C, Sanchez J. High Willingness to Use and Recommend Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention in Peru. Sexually Transmitted Diseases 2025, 53: 162-170. PMID: 41165341, DOI: 10.1097/olq.0000000000002268.Peer-Reviewed Original ResearchAdolescentAdultAnti-Bacterial AgentsDoxycyclineFemaleHealth PersonnelHomosexuality, MaleHumansMaleMiddle AgedPatient Acceptance of Health CarePeruPost-Exposure ProphylaxisSexual PartnersSexually Transmitted DiseasesSexually Transmitted Diseases, BacterialSurveys and QuestionnairesTransgender PersonsYoung Adult
2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Kelley C, Acevedo-Quiñones M, Agwu A, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos V, Clark J, Clement M, Creticos C, Crofoot G, Diaz R, Doblecki-Lewis S, Gallardo-Cartagena J, Gaur A, Grinsztejn B, Hassler S, Hinojosa J, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso M, Valdez Madruga J, Mayer K, Mills A, Mounzer K, Ndlovu N, Novak R, Perez Rios A, Phanuphak N, Ramgopal M, Ruane P, Sánchez J, Santos B, Schine P, Schreibman T, Spencer L, Van Gerwen O, Vasconcelos R, Vasquez J, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown L, Carter C, Das M, Baeten J, Ogbuagu O. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. The New England Journal Of Medicine 2024, 392: 1261-1276. PMID: 39602624, DOI: 10.1056/nejmoa2411858.Peer-Reviewed Original ResearchAcetamidesAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDouble-Blind MethodDrug Administration ScheduleDrug CombinationsEmtricitabineFemaleHIV InfectionsHumansIncidenceIndazolesInjection Site ReactionInjections, SubcutaneousIntention to Treat AnalysisMaleMiddle AgedPre-Exposure ProphylaxisTenofovirTransgender PersonsTreatment OutcomeYoung AdultCabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
Clement M, Hanscom B, Haines D, Bazan J, Chotirosniramit N, Kofron R, Mannheimer S, Mayer K, Silva M, Soto-Torres L, Rinehart A, Rooney J, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz R, Abdalian S, Arduino R, Bazan J, Boyer J, Cabello R, Chariyalertsak S, Clark J, del Rio C, Dunne E, Fichtenbaum C, Frank I, Franks J, Gallardo-Cartagena J, Gaur A, Gonzales P, Grinsztejn B, Gulick R, Ha T, Hall C, Huamani J, Hurt C, Justman J, Kallas E, Kelley C, Landovitz R, Liu A, Losso M, Madruga J, Magnus M, Mayer K, Middelkoop K, Novak R, Overton E, Oyedele T, Phanuphak N, Presti R, Reirden D, Rompalo A, Santos B, Sued O, Swaminathan S, van Dam C. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083. Clinical Infectious Diseases 2024, 82: e387-e395. PMID: 39579334, PMCID: PMC13016779, DOI: 10.1093/cid/ciae572.Peer-Reviewed Original Research